ヨーロッパの遺伝性癌検査市場、検査タイプ別（マルチパネルセット、シングルサイト遺伝子検査）、診断タイプ別（生検、画像診断、ラボ検査）、技術別（シーケンシング、ポリメラーゼ連鎖反応（PCR）、マイクロアレイ）、疾患タイプ別（遺伝性乳癌・卵巣癌症候群、コーデン症候群、リンチ症候群、遺伝性白血病・造血悪性腫瘍症候群、家族性大腸腺腫症（FAP）、リ・フラウメニ症候群、フォン・ヒッペル・リンドウ病、多発性内分泌腫瘍症（MEN）症候群）、エンドユーザー別（病院、診療所、研究所、放射線科センター、診断センター、その他）、流通チャネル別（直接入札、小売販売）、2029年までの動向と予測。
ヨーロッパの遺伝性癌検査市場の分析と洞察
がんは、細胞の機能を制御する遺伝子の特定の変異によって引き起こされる遺伝病であり、特に細胞の増殖と再生に影響を及ぼします。遺伝性の遺伝子変異は、すべてのがんの約5〜10％の原因です。研究者は、特定の遺伝子の変異を、特定のがんの発症を通じて人々に影響を与える50を超える遺伝性がん症候群に関連付けています。さらに、乳がん症例の約5〜10％は、親から受け継いだ遺伝子変異に関連しています。したがって、がんの有病率の増加は遺伝性がんの着実な成長を促進し、したがって遺伝性がん検査市場の成長を促進しています。さらに、非侵襲性検査方法の需要の増加と、より質の高いヘルスケアと早期診断の需要の高まりは、市場成長の大きな機会です。さらに、遺伝性がん検査中に直面する倫理的課題と市場プレーヤー間の競争の激化は、市場成長の重要な課題です。
しかし、がん診断に関する厳格な規制と検査に伴う高額な費用が市場の成長を妨げる可能性があります。
Data Bridge Market Research の分析によると、ヨーロッパの遺伝性癌検査市場は、予測期間中に 12.4% の CAGR で成長し、2029 年までに 42 億 8,912 万米ドルに達すると予想されています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019 - 2015 にカスタマイズ可能) |
|
定量単位 |
売上高（百万米ドル）、販売数量（個数）、価格（米ドル） |
|
対象セグメント |
検査タイプ（マルチパネルセット、および単一部位遺伝子検査）、診断タイプ（生検、画像診断、臨床検査）、技術（シーケンシング、ポリメラーゼ連鎖反応（PCR）、マイクロアレイ）、疾患タイプ（遺伝性乳がんおよび卵巣がん症候群、コーデン症候群、リンチ症候群、遺伝性白血病および造血悪性腫瘍症候群、家族性大腸腺腫症（FAP）、リ・フラウメニ症候群、フォン・ヒッペル・リンドウ病、多発性内分泌腫瘍症（MEN）症候群）、エンドユーザー（病院、クリニック、研究所、放射線科センター、診断センター、その他）、流通チャネル（直接入札、小売販売）別。 |
|
対象国 |
ドイツ、フランス、イギリス、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他のヨーロッパ諸国。 |
|
対象となる市場プレーヤー |
Invitae Corporation、Illumina, Inc.、Natera, Inc.、CENTOGENE NV、4baseCare、Biocartis、Fulgent Genetics、Ambry Genetics、BioReference、PerkinElmer Inc.、LifeLabs、Abbott、BIO-HELIX、Cepheid、Eurofins Scientific など。 |
欧州遺伝性癌検査市場の定義
遺伝性癌とは、遺伝的変異が受け継がれることで起こる癌のことです。特定の遺伝子の有害な変異は、癌のリスク増加と関連しています。遺伝子検査により、癌を発症する生涯リスクを推定できます。これは、遺伝子、染色体、またはタンパク質の変異を調べることで行うことができます。遺伝子検査は、いくつかの種類の癌で利用できます。これには、乳癌、卵巣癌、結腸癌、甲状腺癌、前立腺癌、膵臓癌、皮膚癌、肉腫、腎臓癌、胃癌が含まれます。多くの医学的研究により、一般的な癌の 5% から 10% が遺伝性であると考えられています。遺伝子検査は、人が有害な遺伝子変異を持っているかどうかを判断するために行われます。これらの検査は、まだ癌にかかっていない家族が、癌感受性の代替物を持っていることがわかっている家族と同じ変異を受け継いでいるかどうかを判断するのにも役立ちます。
欧州の遺伝性癌検査市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 遺伝性癌の発生率上昇
がんは、細胞の制御されない増殖から生じます。がんは、細胞の成長と分裂を制御する遺伝情報（遺伝子）の有害な変化（突然変異）によって発生し、細胞が効果的に機能できなくなります。
In hereditary cancer cases, the individual inherits a copy of the mutated growth regulatory gene from one parent and a working copy of the same gene from the other parent. The mutated gene is also called a "cancer susceptibility gene." As this cancer-susceptibility gene is inherited, it is found in every cell in the body, but a working copy of the gene keeps each cell functioning properly. However, if a mutation damages a functional copy of a gene in a cell, the cell can lose control of its growth and become cancerous. Thus, individuals who inherit a cancer gene are much more likely to develop certain cancers during their lifetime.
Thus, rising incidences of hereditary cancer increase the demand for hereditary cancer testing and may act as a driver for the growth of the Europe hereditary cancer testing market.
- Increase In The Geriatric Population
Cancer can be a disease of aging patients. Across the globe, the geriatric population is increasing. The risk of hereditary cancer among geriatrics is much more. The rising geriatric population can result in better provision of the Europe hereditary cancer testing market. It anticipated an upsurge in demand in the Europe hereditary cancer testing market. An aging population is causing a redistribution of the demographic structure that will affect the future of health care. Undoubtedly, the risk of cancer increases exponentially with age.
Hereditary cancer, including its incidence and associated risk, using the world's largest complete family structure and medically confirmed cancer database, was approximately twice as high in the population aged 8-20 years born to affected parents or siblings of people who have no relatives. The risk of small bowel, testicular, thyroid, and bone cancers was five to eight times greater.
Thus, the increase in cancer incidences among the geriatric population is expected to be a driving factor for the growth of the Europe hereditary cancer testing market.
Restraint
- High Cost of Hereditary Cancer Testing
Hereditary cancer testing employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing player. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Testing kits are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation, and expensive medications.
- In addition, testing procedures have also been used in cancer testing. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.
Thus, the high cost of cancer testing using advanced modalities and technology products may be a major restraining factor for the growth of the Europe hereditary cancer testing market.
Opportunity
-
Strategic Initiatives By Market Players
The rise in the Europe hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.
These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the Europe hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the Europe hereditary cancer testing market.
Challenge
- Ethical Challenges Faced During Hereditary Cancer Testing
During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.
The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.
Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.
Post-COVID-19 Impact on Europe Hereditary Cancer Testing Market
Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the Europe hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the Europe hereditary cancer testing market during the forecast period.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.
Recent Developments
- In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.
- In March 2022, Illumina, Inc. introduced the n vitro diagnostic (IVD) kit, a cancer RNA sequencer. The launch resulted in expansion of the sequencing product line, followed by post market approval.It is depicted to show a linear market growth.
Europe Hereditary Cancer Testing Market Scope
Europe hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY TEST TYPE
- MULTI PANEL TEST
- SINGLE SITE GENETIC TEST
On the basis of test type, the Europe hereditary cancer testing market is segmented into multi panel test and single site genetic test.
BY DIAGNOSIS TYPE
- BIOPSY
- IMAGING
- LAB TESTS
On the basis of diagnosis type, the Europe hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.
BY TECHNOLOGY
- SEQUENCING
- POLYMERASE CHAIN REACTION (PCR)
- MICROARRAY
On the basis of technology, the Europe hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.
BY DISEASE TYPE
- HEREDITARY BREAST & OVARIAN CANCER SYNDROME
- COWDEN SYNDROME
- LYNCH SYNDROME
- HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
- FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
- LI-FRAUMENI SYNDROME
- VON HIPPEL-LINDAU DISEASE
- MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES
On the basis of disease type, the Europe hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.
BY END USER
On the basis of end user, the Europe hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.
BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
On the basis of distribution channel, the Europe hereditary cancer testing market is segmented into direct tender, retail sales.
Europe Hereditary Cancer Testing Market Regional Analysis/Insights
The Europe hereditary cancer testing market is analyzed and market size information is provided by test type, diagnosis type, technology, disease type, end user, and distribution channel.
The countries covered in this market report Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the rest of Europe.
- In 2022, Germany is expected to grow due to its advanced technology and inventions for the diagnosis of cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Hereditary Cancer Testing Market Share Analysis
Europe hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe hereditary cancer testing market.
Some of the major players operating in the Europe hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.
Research Methodology: Europe Hereditary Cancer Testing Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HEREDITARY CANCER TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EUROPE HEREDITARY CANCER TESTING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER
6.1.2 INCREASE IN THE GERIATRIC POPULATION
6.1.3 RISING HEALTHCARE SPENDING
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING
6.2 RESTRAINTS
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING
6.2.2 LACK OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES
6.4 CHALLENGES
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS
7 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 MULTI PANEL TEST
7.3 SINGLE-SITE GENETIC TEST
8 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE
8.1 OVERVIEW
8.2 BIOPSY
8.2.1 NEEDLE BIOPSIES
8.2.2 ENDOSCOPIC BIOPSIES
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY
8.2.4 LAPAROTOMY AND THORACOTOMY
8.2.5 OTHERS
8.3 IMAGING
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 NUCLEAR SCAN
8.3.5 ULTRASOUND
8.3.6 X-RAYS
8.4 LAB TESTS
8.4.1 BLOOD
8.4.2 URINE
8.4.3 OTHERS
9 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION (PCR)
9.3 SEQUENCING
9.4 MICRO ARRAY
10 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME
10.3 COWDEN SYNDROME
10.4 LYNCH SYNDROME
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
10.7 LI-FRAUMENI SYNDROME
10.8 VON HIPPEL-LINDAU DISEASE
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME
11 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 RADIOLOGY CENTERS
11.6 LABORATORIES
11.7 OTHERS
12 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 EUROPE HEREDITARY CANCER TESTING MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 RUSSIA
13.1.5 ITALY
13.1.6 SPAIN
13.1.7 TURKEY
13.1.8 NETHERLANDS
13.1.9 SWITZERLAND
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
14 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 ILLUMINA, INC. (2021)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PERKINELMER INC. (2021)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LIFELABS GENETICS
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 EUROFINS SCIENTIFIC (2021)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AMBRY GENETICS
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BIOCARTIS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIO-HELIX
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CENTOGENE N.V. (2021)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 FULGENT GENETICS
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 INVITAE CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 NATERA, INC. (2021)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 4BASECARE.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 12 EUROPE POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 EUROPE HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 41 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 43 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 45 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 46 GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 47 GERMANY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 50 GERMANY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 GERMANY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 GERMANY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 54 GERMANY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 56 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 57 FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 58 FRANCE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 59 FRANCE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 60 FRANCE IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 FRANCE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 65 FRANCE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 68 U.K. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 69 U.K. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.K. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.K. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.K. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.K. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 74 U.K. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.K. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 76 U.K. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 78 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 79 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 80 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 81 RUSSIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 82 RUSSIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 83 RUSSIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 84 RUSSIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 89 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 90 ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 91 ITALY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 92 ITALY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 93 ITALY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 94 ITALY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 95 ITALY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 96 ITALY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 98 ITALY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 100 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 101 SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 102 SPAIN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 103 SPAIN BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 104 SPAIN IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 105 SPAIN LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 106 SPAIN HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 107 SPAIN HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 108 SPAIN HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 109 SPAIN HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 111 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 112 TURKEY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 113 TURKEY HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 114 TURKEY BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 115 TURKEY IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 116 TURKEY LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 117 TURKEY HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 TURKEY HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 119 TURKEY HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 120 TURKEY HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 121 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 122 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 123 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 124 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 129 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 130 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 131 NETHERLANDS HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 134 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 135 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 136 SWITZERLAND BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 137 SWITZERLAND IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 138 SWITZERLAND LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 139 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 140 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 141 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 142 SWITZERLAND HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 143 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 144 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 145 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 146 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 147 BELGIUM BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 148 BELGIUM IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 149 BELGIUM LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 150 BELGIUM HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 152 BELGIUM HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 153 BELGIUM HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 154 REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 EUROPE HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HEREDITARY CANCER TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE EUROPE HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD
FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HEREDITARY CANCER TESTING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HEREDITARY CANCER TESTING MARKET
FIGURE 14 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021
FIGURE 15 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021
FIGURE 19 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE
FIGURE 22 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021
FIGURE 23 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 24 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 25 EUROPE HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021
FIGURE 27 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 29 EUROPE HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 30 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, 2021
FIGURE 31 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 EUROPE HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 36 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 EUROPE HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)
FIGURE 39 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)
FIGURE 40 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 EUROPE HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 EUROPE HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)
FIGURE 43 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
